Brief: Alphamab Oncology Says Got IND Approval From National Medical Products Administration Of China
27/10/2022 16:11
Oct 27 (Reuters) - Alphamab Oncology 9966.HK :
* GOT IND APPROVAL FROM NATIONAL MEDICAL PRODUCTS
ADMINISTRATION
OF CHINA FOR INITIATING A PHASE IA/IB CLINICAL TRIAL OF JSKN003
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)